v3.26.1
Income Taxes (Tables)
 12 Months Ended
Mar. 31, 2026
Income taxes paid (refund) [abstract]  
Schedule of Composition of Income Tax Expense (Benefit)
The composition of income tax expense (benefit) is as follows:
JPY (millions)
For the Year Ended March 31
202420252026
Current tax expense
¥107,349 ¥138,057 ¥110,804 
Deferred tax benefit
(198,755)(71,116)(101,034)
Total
¥(91,406)¥66,941 ¥9,770 
Schedule of Reconciliation from Income Tax Expense (Benefit)
The following is a reconciliation from income tax expense at Takeda's domestic (Japanese) statutory tax rate to Takeda's income tax expense (benefit) reported for the year ended March 31:
JPY (millions)
202420252026
Profit (loss) before tax
¥52,791 ¥175,084 ¥(142,355)
Income tax expense (benefit) at Takeda’s domestic (Japanese) statutory tax rate of 30.6%
16,143 53,541 (43,532)
Non-deductible expenses for tax purposes *1
21,353 25,860 59,712 
Changes in unrecognized deferred tax assets and deferred tax liabilities *2
(3,512)45,243 41,340 
Tax credits
(30,654)(28,371)(14,840)
Differences in applicable tax rates of overseas subsidiaries *3
(29,782)(39,963)(32,538)
Changes in tax effects of undistributed profit of overseas subsidiaries
(1,737)10,282 2,089 
Effect of changes in applicable tax rates and tax law *4
(11,994)(6,964)(2,939)
Tax contingencies *5
(83,784)426 (1,309)
Effect of prior year items
(2,479)3,305 (8,323)
Entity reorganizations/Divestments
33,469 2,880 4,279 
Other
1,571 702 5,831 
Income tax expense (benefit) reported for the year¥(91,406)¥66,941 ¥9,770 
*1Amounts for the years ended March 31, 2024, 2025 and 2026 include the impact from intra territory eliminations, the pre-tax effect of which has been eliminated in arriving at Takeda’s consolidated income from continuing operations before income taxes. Additionally, amounts for the years ended March 31, 2024, 2025 and 2026 include non-deductible interest due to Japanese earnings stripping rules. Amount for the year ended March 31, 2026 includes JPY 14,125 million related to impairment of discontinued cell therapy platform assets to which a deferred tax liability was not initially recognized in accordance with the recognition exception under IAS 12.15.
*2Amounts for the years ended March 31, 2024, 2025 and 2026 include deferred tax expenses (benefits) associated with carried forward net operating losses. Amount for the year ended March 31, 2025 includes JPY 21,600 million of deferred tax expense related to derecognition of previously recognized interest expense carryforwards under Japanese earnings stripping rules. Amount for the year ended March 31, 2026 is driven by tax expense resulting from the recognition of provision for legal proceedings resulting from the Amitiza jury verdict.
*3Amounts for the years ended March 31, 2024, 2025 and 2026 include unitary and minimum taxes on overseas subsidiaries. Amounts for the years ended March 31, 2025 and 2026 also include Pillar Two taxes on overseas subsidiaries.
*4Amount for the year ended March 31, 2024 includes JPY 4,206 million deferred tax expense related to U.S. state law change and JPY 16,200 million deferred tax benefit relating to extension of the carryforward period relating to Japanese earnings stripping rules. Amount for the year ended March 31, 2025 includes JPY 5,809
million deferred tax benefit related to U.S. state law changes. Amounts for the years ended March 31, 2025 and 2026 include JPY 1,155 million and JPY 4,797 million deferred tax benefit related to the change in Japan's enacted tax rate (from 30.6% to 31.5%) for years beginning April 1, 2026.
*5Tax benefit for the year ended March 31, 2024 is from favorable resolutions of tax contingencies including JPY 63,547 million relating to the settlement with Irish Revenue Commissioners with respect to a tax assessment related to the treatment of an acquisition break fee Shire received from AbbVie in 2014.
Schedule of Deferred Taxes
Deferred tax assets and liabilities reported in the consolidated statements of financial position are as follows:
JPY (millions)
As of March 31
20252026
Deferred tax assets
¥370,745 ¥546,260 
Deferred tax liabilities
(35,153)(26,804)
Net deferred tax assets
¥335,592 ¥519,456 
The major items and changes in deferred tax assets and liabilities are as follows:
JPY (millions)
As of April 1, 2024Recognized in profit or (loss)Recognized in other comprehensive income
Other*
As of March 31, 2025
Research and development expenses¥217,010 ¥53,732 ¥— ¥9,816 ¥280,558 
Inventories138,402 64,265 — (10,788)191,879 
Property, plant and equipment(68,509)5,332 — (1,839)(65,016)
Intangible assets(390,270)65,032 — (16,599)(341,837)
Financial assets measured at FVTOCI(7,639)— 4,235 1,119 (2,285)
Accrued expenses and provisions185,593 (75,010)— 7,624 118,207 
Defined benefit plans14,728 (3,768)2,231 375 13,566 
Deferred income5,493 (875)— 41 4,659 
Unused tax losses88,671 (36,355)— 2,973 55,289 
Tax credits46,159 (21,469)— 2,664 27,354 
Investments in subsidiaries and associates(26,801)17,595 — (361)(9,567)
Cash flow hedges21,645 2,969 3,775 1,461 29,850 
Other55,606 (332)(3,350)(18,989)32,935 
Total¥280,088 ¥71,116 ¥6,891 ¥(22,503)¥335,592 
JPY (millions)
As of April 1, 2025Recognized in profit or (loss)Recognized in other comprehensive income
Other*
As of March 31, 2026
Research and development expenses¥280,558 ¥(124,569)¥— ¥3,694 ¥159,683 
Inventories191,879 (18,055)— 13,064 186,888 
Property, plant and equipment(65,016)2,767 — (2,570)(64,819)
Intangible assets(341,837)64,714 — (15,456)(292,579)
Financial assets measured at FVTOCI(2,285)— 1,941 (3,567)(3,911)
Accrued expenses and provisions118,207 80,641 — 19,246 218,094 
Defined benefit plans13,566 (877)(468)2,016 14,237 
Deferred income4,659 (541)— 46 4,164 
Unused tax losses55,289 77,864 57,635 17,343 208,131 
Tax credits27,354 20,816 — 4,503 52,673 
Investments in subsidiaries and associates(9,567)3,259 — 437 (5,871)
Cash flow hedges29,850 4,156 (10,626)(1,246)22,134 
Other32,935 (9,141)(3,051)(111)20,632 
Total¥335,592 ¥101,034 ¥45,431 ¥37,399 ¥519,456 
* Other consists primarily of foreign currency translation differences, reclassification of deferred tax assets and liabilities classified as held for sale and the tax impact of items charged directly to equity.
The unused tax losses, deductible temporary differences, and unused tax credits for which deferred tax assets were not recognized are as follows:
JPY (millions)
As of March 31
20252026
Unused tax losses¥1,183,701 ¥1,207,254 
Deductible temporary differences427,373 713,810 
Unused tax credits26,993 29,422 
The unused tax losses and unused tax credits for which deferred tax assets were not recognized will expire as follows:
JPY (millions)
As of March 31
Unused tax losses20252026
1st year¥114 ¥1,083 
2nd year1,278 2,571 
3rd year2,375 584,870 
4th year549,705 451,420 
5th year469,391 5,374 
After 5th year152,121 142,539 
Indefinite8,717 19,397 
Total¥1,183,701 ¥1,207,254 
JPY (millions)
As of March 31
Unused tax credits20252026
Less than 5 years¥3,715 ¥4,493 
5 years or more23,278 24,929 
Total¥26,993 ¥29,422